Endometrial Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Endometrial Cancer – Pipeline Review, H2 2017’, provides an overview of the Endometrial Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer

The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects

The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Ability Pharmaceuticals SL

Advenchen Laboratories LLC

Aeterna Zentaris Inc

ArQule Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

CBT Pharmaceuticals Inc

Critical Outcome Technologies Inc

CytomX Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Galena Biopharma Inc

GamaMabs Pharma SA

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Gradalis Inc

Horizon Pharma Plc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Innate Pharma SA

Innovation Pharmaceuticals Inc

Karyopharm Therapeutics Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Millennium Pharmaceuticals Inc

Moderna Therapeutics Inc

Novartis AG

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Pivot Pharmaceuticals Inc

PTC Therapeutics Inc

Puma Biotechnology Inc

Sanofi

Shenogen Pharma Group Ltd

Sigma-Tau SpA

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Tesaro Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Endometrial Cancer - Overview 11

Endometrial Cancer - Therapeutics Development 12

Pipeline Overview 12

Pipeline by Companies 13

Pipeline by Universities/Institutes 18

Products under Development by Companies 19

Products under Development by Universities/Institutes 25

Endometrial Cancer - Therapeutics Assessment 26

Assessment by Target 26

Assessment by Mechanism of Action 31

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Endometrial Cancer - Companies Involved in Therapeutics Development 40

AbbVie Inc 40

Ability Pharmaceuticals SL 40

Advenchen Laboratories LLC 41

Aeterna Zentaris Inc 41

ArQule Inc 41

Arrien Pharmaceuticals LLC 42

AstraZeneca Plc 42

AVEO Pharmaceuticals Inc 43

Bayer AG 43

BeiGene Ltd 44

BioNTech AG 44

Biscayne Pharmaceuticals Inc 45

Boehringer Ingelheim GmbH 45

CBT Pharmaceuticals Inc 46

Critical Outcome Technologies Inc 46

CytomX Therapeutics Inc 46

Eisai Co Ltd 47

Eli Lilly and Co 47

Esperance Pharmaceuticals Inc 48

Exelixis Inc 48

F. Hoffmann-La Roche Ltd 49

Galena Biopharma Inc 49

GamaMabs Pharma SA 50

Genmab A/S 50

GlaxoSmithKline Plc 51

Glycotope GmbH 51

Gradalis Inc 51

Horizon Pharma Plc 52

Immunocore Ltd 52

ImmunoGen Inc 53

Immunomedics Inc 53

Incyte Corp 54

Innate Pharma SA 54

Innovation Pharmaceuticals Inc 55

Karyopharm Therapeutics Inc 55

MedImmune LLC 56

Merck & Co Inc 56

Merck KGaA 57

Merrimack Pharmaceuticals Inc 57

Mersana Therapeutics Inc 58

Merus NV 58

Millennium Pharmaceuticals Inc 59

Moderna Therapeutics Inc 59

Novartis AG 59

OncoResponse Inc 60

Ono Pharmaceutical Co Ltd 60

Pfizer Inc 61

Pharma Mar SA 61

Pivot Pharmaceuticals Inc 62

PTC Therapeutics Inc 62

Puma Biotechnology Inc 63

Sanofi 63

Shenogen Pharma Group Ltd 64

Sigma-Tau SpA 64

Sutro Biopharma Inc 64

Syndax Pharmaceuticals Inc 65

Synthon Holdings BV 65

Taiho Pharmaceutical Co Ltd 66

Tesaro Inc 66

Vyriad Inc 66

Endometrial Cancer - Drug Profiles 68

212 Pb-TCMC-Trastuzumab - Drug Profile 68

2X-121 - Drug Profile 70

2X-131 - Drug Profile 72

ABTL-0812 - Drug Profile 73

AEZS-138 - Drug Profile 76

AL-3818 - Drug Profile 77

anetumab ravtansine - Drug Profile 80

ARN-3261 - Drug Profile 83

atezolizumab - Drug Profile 84

AV-203 - Drug Profile 107

avelumab - Drug Profile 110

AZD-5363 - Drug Profile 123

BAY-1082439 - Drug Profile 126

BAY-1895344 - Drug Profile 127

BGB-283 - Drug Profile 128

BGBA-317 - Drug Profile 131

BIS-1602 - Drug Profile 136

buparlisib hydrochloride - Drug Profile 138

cabozantinib s-malate - Drug Profile 144

CBT-501 - Drug Profile 166

Cellular Immunotherapy for Oncology - Drug Profile 168

Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile 169

Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile 171

COTI-2 - Drug Profile 172

cridanimod - Drug Profile 181

CX-2009 - Drug Profile 183

durvalumab - Drug Profile 185

durvalumab + tremelimumab - Drug Profile 205

emactuzumab - Drug Profile 212

endoxifen hydrochloride - Drug Profile 213

entinostat - Drug Profile 214

EP-100 - Drug Profile 222

EP-200 - Drug Profile 224

epacadostat - Drug Profile 225

everolimus - Drug Profile 234

FAZ-053 - Drug Profile 246

GALE-301 - Drug Profile 247

gedatolisib - Drug Profile 253

gemogenovatucel-T - Drug Profile 255

GM-102 - Drug Profile 260

GSK-2256098 - Drug Profile 262

GSK-2636771 - Drug Profile 264

HO-3867 - Drug Profile 265

HuMax-AXL-ADC - Drug Profile 266

IMCD-104C - Drug Profile 267

INCAGN-1876 - Drug Profile 268

INCAGN-1949 - Drug Profile 270

INCB-50465 - Drug Profile 272

INCB-54828 - Drug Profile 274

interferon gamma-1b - Drug Profile 276

itacitinib adipate - Drug Profile 281

Kevetrin - Drug Profile 285

lenvatinib mesylate - Drug Profile 297

lurbinectedin - Drug Profile 316

LY-3023414 - Drug Profile 327

M-9831 - Drug Profile 329

MCLA-128 - Drug Profile 330

MCS-110 - Drug Profile 333

miransertib - Drug Profile 335

mirvetuximab soravtansine - Drug Profile 339

MK-2206 - Drug Profile 346

MM-161 - Drug Profile 349

MM-310 - Drug Profile 350

monalizumab - Drug Profile 352

Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile 356

mRNA-4157 - Drug Profile 357

namitecan - Drug Profile 358

neratinib - Drug Profile 359

nintedanib - Drug Profile 380

niraparib - Drug Profile 392

nivolumab - Drug Profile 401

ONC-201 - Drug Profile 452

ONCO-101 - Drug Profile 461

Oncolytic Virus to Activate IFNb and SLC5A5 for Endometrial Cancer - Drug Profile 462

Oncolytic Virus to Activate IFNB and SLC5A5 for Hematological Malignancies - Drug Profile 463

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile 465

ONCR-201 - Drug Profile 466

palbociclib - Drug Profile 467

PankoMab-GEX - Drug Profile 480

PDR-001 - Drug Profile 482

pembrolizumab - Drug Profile 485

Peptides to Antagonize GnRH II Receptor for Oncology - Drug Profile 550

pimasertib hydrochloride + voxtalisib - Drug Profile 551

PM-184 - Drug Profile 553

PRI-724 - Drug Profile 555

PTC-596 - Drug Profile 557

PVT-005 - Drug Profile 559

sacituzumab - Drug Profile 560

sapanisertib - Drug Profile 573

SAR-408701 - Drug Profile 577

SC-004 - Drug Profile 579

selinexor - Drug Profile 580

sirolimus albumin-bound - Drug Profile 603

Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile 605

SNG-1153 - Drug Profile 606

SP-2509 - Drug Profile 607

Stem Cell Therapy to Activate SLC5A5 for Oncology - Drug Profile 608

STRO-002 - Drug Profile 609

TAS-117 - Drug Profile 610

tisotumab vedotin - Drug Profile 611

trametinib dimethyl sulfoxide + uprosertib - Drug Profile 614

trastuzumab duocarmazine - Drug Profile 616

TSR-042 - Drug Profile 619

vistusertib - Drug Profile 621

XMT-1536 - Drug Profile 624

Endometrial Cancer - Dormant Projects 626

Endometrial Cancer - Discontinued Products 628

Endometrial Cancer - Product Development Milestones 629

Featured News & Press Releases 629

Appendix 639

Methodology 639

Coverage 639

Secondary Research 639

Primary Research 639

Expert Panel Validation 639

Contact Us 639

Disclaimer 640

List of Tables

List of Tables

Number of Products under Development for Endometrial Cancer, H2 2017 19

Number of Products under Development by Companies, H2 2017 21

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 24

Number of Products under Development by Universities/Institutes, H2 2017 25

Products under Development by Companies, H2 2017 26

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 27

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 28

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 29

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 30

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 31

Products under Development by Universities/Institutes, H2 2017 32

Number of Products by Stage and Target, H2 2017 34

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 35

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 36

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 37

Number of Products by Stage and Mechanism of Action, H2 2017 39

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 40

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 41

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 42

Number of Products by Stage and Route of Administration, H2 2017 44

Number of Products by Stage and Molecule Type, H2 2017 46

Endometrial Cancer – Pipeline by AbbVie Inc, H2 2017 47

Endometrial Cancer – Pipeline by Ability Pharmaceuticals SL, H2 2017 47

Endometrial Cancer – Pipeline by Advenchen Laboratories LLC, H2 2017 48

Endometrial Cancer – Pipeline by Aeterna Zentaris Inc, H2 2017 48

Endometrial Cancer – Pipeline by ArQule Inc, H2 2017 49

Endometrial Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2017 49

Endometrial Cancer – Pipeline by AstraZeneca Plc, H2 2017 50

Endometrial Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2017 50

Endometrial Cancer – Pipeline by Bayer AG, H2 2017 51

Endometrial Cancer – Pipeline by BeiGene Ltd, H2 2017 51

Endometrial Cancer – Pipeline by BioNTech AG, H2 2017 52

Endometrial Cancer – Pipeline by Biscayne Pharmaceuticals Inc, H2 2017 52

Endometrial Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2017 52

Endometrial Cancer – Pipeline by CBT Pharmaceuticals Inc, H2 2017 53

Endometrial Cancer – Pipeline by Critical Outcome Technologies Inc, H2 2017 53

Endometrial Cancer – Pipeline by CytomX Therapeutics Inc, H2 2017 54

Endometrial Cancer – Pipeline by Eisai Co Ltd, H2 2017 54

Endometrial Cancer – Pipeline by Eli Lilly and Co, H2 2017 55

Endometrial Cancer – Pipeline by Esperance Pharmaceuticals Inc, H2 2017 55

Endometrial Cancer – Pipeline by Exelixis Inc, H2 2017 56

Endometrial Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 56

Endometrial Cancer – Pipeline by Galena Biopharma Inc, H2 2017 57

Endometrial Cancer – Pipeline by GamaMabs Pharma SA, H2 2017 57

Endometrial Cancer – Pipeline by Genmab A/S, H2 2017 57

Endometrial Cancer – Pipeline by GlaxoSmithKline Plc, H2 2017 58

Endometrial Cancer – Pipeline by Glycotope GmbH, H2 2017 58

Endometrial Cancer – Pipeline by Gradalis Inc, H2 2017 59

Endometrial Cancer – Pipeline by Horizon Pharma Plc, H2 2017 59

Endometrial Cancer – Pipeline by Immunocore Ltd, H2 2017 60

Endometrial Cancer – Pipeline by ImmunoGen Inc, H2 2017 60

Endometrial Cancer – Pipeline by Immunomedics Inc, H2 2017 61

Endometrial Cancer – Pipeline by Incyte Corp, H2 2017 61

Endometrial Cancer – Pipeline by Innate Pharma SA, H2 2017 62

Endometrial Cancer – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 62

Endometrial Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2017 63

Endometrial Cancer – Pipeline by MedImmune LLC, H2 2017 63

Endometrial Cancer – Pipeline by Merck & Co Inc, H2 2017 64

Endometrial Cancer – Pipeline by Merck KGaA, H2 2017 64

Endometrial Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 65

Endometrial Cancer – Pipeline by Mersana Therapeutics Inc, H2 2017 65

Endometrial Cancer – Pipeline by Merus NV, H2 2017 66

Endometrial Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 66

Endometrial Cancer – Pipeline by Moderna Therapeutics Inc, H2 2017 66

Endometrial Cancer – Pipeline by Novartis AG, H2 2017 67

Endometrial Cancer – Pipeline by OncoResponse Inc, H2 2017 67

Endometrial Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 68

Endometrial Cancer – Pipeline by Pfizer Inc, H2 2017 68

Endometrial Cancer – Pipeline by Pharma Mar SA, H2 2017 69

Endometrial Cancer – Pipeline by Pivot Pharmaceuticals Inc, H2 2017 69

Endometrial Cancer – Pipeline by PTC Therapeutics Inc, H2 2017 70

Endometrial Cancer – Pipeline by Puma Biotechnology Inc, H2 2017 70

Endometrial Cancer – Pipeline by Sanofi, H2 2017 71

Endometrial Cancer – Pipeline by Shenogen Pharma Group Ltd, H2 2017 71

Endometrial Cancer – Pipeline by Sigma-Tau SpA, H2 2017 71

Endometrial Cancer – Pipeline by Sutro Biopharma Inc, H2 2017 72

Endometrial Cancer – Pipeline by Syndax Pharmaceuticals Inc, H2 2017 72

Endometrial Cancer – Pipeline by Synthon Holdings BV, H2 2017 72

Endometrial Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 73

Endometrial Cancer – Pipeline by Tesaro Inc, H2 2017 73

Endometrial Cancer – Pipeline by Vyriad Inc, H2 2017 74

Endometrial Cancer – Dormant Projects, H2 2017 633

Endometrial Cancer – Dormant Projects, H2 2017 (Contd..1), H2 2017 634

Endometrial Cancer – Discontinued Products, H2 2017 635

List of Figures

List of Figures

Number of Products under Development for Endometrial Cancer, H2 2017 19

Number of Products under Development by Companies, H2 2017 20

Number of Products under Development by Universities/Institutes, H2 2017 25

Number of Products by Top 10 Targets, H2 2017 33

Number of Products by Stage and Top 10 Targets, H2 2017 33

Number of Products by Top 10 Mechanism of Actions, H2 2017 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 38

Number of Products by Routes of Administration, H2 2017 43

Number of Products by Stage and Routes of Administration, H2 2017 43

Number of Products by Top 10 Molecule Types, H2 2017 45

Number of Products by Stage and Top 10 Molecule Types, H2 2017 45

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports